JP2021522844A5 - - Google Patents
Info
- Publication number
- JP2021522844A5 JP2021522844A5 JP2020564248A JP2020564248A JP2021522844A5 JP 2021522844 A5 JP2021522844 A5 JP 2021522844A5 JP 2020564248 A JP2020564248 A JP 2020564248A JP 2020564248 A JP2020564248 A JP 2020564248A JP 2021522844 A5 JP2021522844 A5 JP 2021522844A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- car
- acid sequence
- domain
- antigen
- Prior art date
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023064079A JP7733051B2 (ja) | 2018-05-15 | 2023-04-11 | キメラ抗原受容体 |
| JP2024166189A JP2024174023A (ja) | 2018-05-15 | 2024-09-25 | キメラ抗原受容体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1807866.7 | 2018-05-15 | ||
| GBGB1807866.7A GB201807866D0 (en) | 2018-05-15 | 2018-05-15 | Chimeric antigen receptor |
| GB1809773.3 | 2018-06-14 | ||
| GBGB1809773.3A GB201809773D0 (en) | 2018-06-14 | 2018-06-14 | Chimeric antigen receptor |
| PCT/GB2019/051330 WO2019220109A1 (en) | 2018-05-15 | 2019-05-15 | Chimeric antigen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023064079A Division JP7733051B2 (ja) | 2018-05-15 | 2023-04-11 | キメラ抗原受容体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522844A JP2021522844A (ja) | 2021-09-02 |
| JP2021522844A5 true JP2021522844A5 (https=) | 2022-03-07 |
| JPWO2019220109A5 JPWO2019220109A5 (https=) | 2022-03-07 |
| JP7335272B2 JP7335272B2 (ja) | 2023-08-29 |
Family
ID=66641159
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564248A Active JP7335272B2 (ja) | 2018-05-15 | 2019-05-15 | キメラ抗原受容体 |
| JP2023064079A Active JP7733051B2 (ja) | 2018-05-15 | 2023-04-11 | キメラ抗原受容体 |
| JP2024166189A Pending JP2024174023A (ja) | 2018-05-15 | 2024-09-25 | キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023064079A Active JP7733051B2 (ja) | 2018-05-15 | 2023-04-11 | キメラ抗原受容体 |
| JP2024166189A Pending JP2024174023A (ja) | 2018-05-15 | 2024-09-25 | キメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11963981B2 (https=) |
| EP (1) | EP3794034A1 (https=) |
| JP (3) | JP7335272B2 (https=) |
| CN (2) | CN112119096B (https=) |
| AU (2) | AU2019269118B2 (https=) |
| CA (1) | CA3099831A1 (https=) |
| WO (1) | WO2019220109A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| AU2019269118B2 (en) * | 2018-05-15 | 2025-02-27 | Autolus Limited | Chimeric antigen receptor |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| WO2021099944A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof |
| GB201919061D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| CN111072776A (zh) * | 2019-12-26 | 2020-04-28 | 成都欧林生物科技股份有限公司 | 抗SpA5蛋白的单克隆抗体及其应用和包含其的试剂盒 |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022140388A1 (en) * | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| JP2025516531A (ja) | 2022-05-11 | 2025-05-30 | オートラス リミテッド | 高リスクまたは再発性小児急性リンパ芽球性白血病のｃｄ１９／２２ ｃａｒ ｔ細胞処置 |
| CN116376920A (zh) * | 2023-03-10 | 2023-07-04 | 中山大学附属第五医院 | Ceacam5靶向的car-t细胞的制备方法及应用 |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
| NL2037929B1 (en) | 2024-06-11 | 2026-01-12 | Prinses Maxima Centrum Voor Kinderoncologie B V | Brain Organoid |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| US20160296562A1 (en) | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| WO2016090337A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| US10738116B2 (en) | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| PT3294764T (pt) | 2015-05-15 | 2021-02-15 | Hope City | Composições de recetores de antigénios quiméricos |
| CN107708741A (zh) * | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| AU2019269118B2 (en) * | 2018-05-15 | 2025-02-27 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
-
2019
- 2019-05-15 AU AU2019269118A patent/AU2019269118B2/en active Active
- 2019-05-15 WO PCT/GB2019/051330 patent/WO2019220109A1/en not_active Ceased
- 2019-05-15 CN CN201980032776.2A patent/CN112119096B/zh active Active
- 2019-05-15 EP EP19726081.3A patent/EP3794034A1/en active Pending
- 2019-05-15 CA CA3099831A patent/CA3099831A1/en active Pending
- 2019-05-15 US US17/054,670 patent/US11963981B2/en active Active
- 2019-05-15 JP JP2020564248A patent/JP7335272B2/ja active Active
- 2019-05-15 CN CN202410424809.0A patent/CN118440211A/zh active Pending
-
2022
- 2022-04-18 US US17/723,209 patent/US11590170B2/en active Active
-
2023
- 2023-04-11 JP JP2023064079A patent/JP7733051B2/ja active Active
-
2024
- 2024-03-06 US US18/597,357 patent/US20250019434A1/en active Pending
- 2024-09-25 JP JP2024166189A patent/JP2024174023A/ja active Pending
-
2025
- 2025-02-17 AU AU2025201086A patent/AU2025201086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522844A5 (https=) | ||
| JP7514746B2 (ja) | 細胞 | |
| JPWO2019220109A5 (https=) | ||
| EP3581651A1 (en) | Anti-gprc5d antibody and molecule containing same | |
| JP2018532766A5 (https=) | ||
| JP2019116474A5 (https=) | ||
| JP2020525032A5 (https=) | ||
| JP2018508215A5 (https=) | ||
| IL302278A (en) | Combination treatment | |
| JP2020533004A5 (https=) | ||
| JP2019535262A5 (https=) | ||
| JP2020515277A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| WO2022060832A1 (en) | Cd33 antibodies | |
| JP2016529213A5 (https=) | ||
| JPWO2023034922A5 (https=) | ||
| JP2025513588A (ja) | 抗ｉｌｔ３抗体およびその使用 | |
| JP2020509745A5 (https=) | ||
| KR20230025655A (ko) | 암 치료용 조성물 및 방법 | |
| CA3241115A1 (en) | Molecules that bind to cd94/nkg2a heterodimer polypeptides | |
| JPWO2020102555A5 (https=) | ||
| JPWO2021226289A5 (https=) | ||
| JPWO2021224629A5 (https=) | ||
| CN120882746A (zh) | 结合至nkg2a和pd-l1的药剂及其用途 | |
| CN116507634A (zh) | Nkp30结合剂 |